Navigation Links
InBios Obtains BARDA Funding to Develop Point-of-Care COVID-19 Test

InBios International Inc., a leading developer of diagnostic tests for emerging infectious diseases, announced today that it had been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to develop the SCoV-2 Detect IgM/IgG Rapid Test, a point-of-care test for detection of SCoV-2 specific IgM/IgG antibodies.

The lateral flow serodiagnostic test will use blood products, from finger-prick samples, to identify people infected with severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. This point-of-care assay will detect SARS-CoV-2 reactive antibodies as host biomarkers.

Under the agreement, InBios will acquire reagents, including patient samples, develop product kits and carry out performance studies to validate the assay design for Emergency Use Authorization (EUA) submission to the U.S. Food and Drug Administration (FDA). Support from BARDA is expected to accelerate the progress toward EUA submission. Earlier this month, InBios received EUA for its Smart DetectTM SARS-CoV-2 rRT-PCR Kit.

“As we all know, time is of the essence during this pandemic, and a robust serological test is needed to quickly and easily identify symptomatic, as well as high-risk asymptomatic, individuals who can be carriers responsible for a large percentage of person-to-person transmission,” said Dr. Syamal Raychaudhuri, InBios’ chief scientific officer. “This funding from BARDA enables InBios to rapidly mobilize to develop this test for the EUA purpose.”

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, Division of Research Innovation and Ventures under Contract No. 75A50120C00090.

For more information about InBios COVID-19 tests, visit:

For more information on COVID-19, please visit or

About InBios: InBios International Inc. specializes in the design, development and manufacture of diagnostic devices for emerging infectious diseases and biothreats. Founded in 1996 in Seattle, WA, our superior quality products are accurate, easy to use and cost effective. InBios offers an extensive catalog of life science reagents, along with a portfolio of more than 25 diagnostic products, including an FDA Emergency Use Authorization for our Smart DetectTM SARS-CoV-2 rRT-PCR Kit and FDA-cleared ELISA kits for Zika, dengue, and West Nile and rapid test kits for Chagas and leishmaniasis. InBios is GMP compliant, FDA registered, USDA licensed and ISO 13485:2016 certified. For more information, visit

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related biology news :

1. Spanish scientist obtains international award for 3-D video of a journey to the interior of a cicada
2. Law Firm Carey Rodriguez Obtains First-Of-Its-Kind Ruling In Landmark Biometric Privacy Case
3. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
4. 4 projects awarded Discovery Transformation Grant funding by Minnesota Partnership
5. Funding for animal testing alternative
6. Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
7. UTSA chemist awarded $300,000 in NASA funding to build lab on a robot prototype
8. Geneticists receive funding to improve citrus production and health
9. 83 global health innovations receive Grand Challenges Canada funding
10. NIH director warns that US research funding is falling behind, calls for new focus on innovation
11. BBSRC announces £10M of funding for advanced scientific equipment
Post Your Comments:
(Date:5/21/2020)... N.J. (PRWEB) , ... May 20, 2020 , ... ... development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer ... Cell & Gene Therapy, will be presenting at the ISCT 2020 Paris Virtual ...
(Date:5/21/2020)... ... May 21, 2020 , ... Agility Orthopedics, home ... Greater Boston area, is pleased to announce a partnership with Dallas-based Simple Interact ... practices in the area, Agility Orthopedics is focused on speeding up patient workflows ...
(Date:5/14/2020)... ... May 12, 2020 , ... ... accurately and easily project contracted liabilities with payers, providers and pharmacies – ... discounts/rebates to Commercial and Government entities, Copay and Patient Assistance Program liabilities ...
Breaking Biology News(10 mins):
(Date:6/3/2020)... (PRWEB) , ... June 03, 2020 , ... ... to highlight various applications of biofeedback. In the next installment, Dr. Inna Khazan ... practice whereby individuals learn to bring their attention to the feelings, thoughts, and ...
(Date:5/28/2020)... ... May 28, 2020 , ... The Security Industry Association (SIA) and ... winners of the Women in Biometrics Awards – a globally recognized program ... Update and the SIA Women in Security Forum . The honorees will ...
(Date:5/21/2020)... CITY, Calif. (PRWEB) , ... May 20, 2020 ... ... announce the addition of Simon Prakash, who will serve as the company’s executive ... joins at a time when Exo is disrupting the medical imaging space, bringing ...
(Date:5/14/2020)... ... 12, 2020 , ... DuPont Nutrition & Biosciences (N&B) has ... personal care ingredients in Russia and Belarus. Beginning May 1, Interdisp JCS will ... care. , The GENENCARE®OSMS product line contains a range of all-natural, ...
Breaking Biology Technology: